We examined the efficacy and safety of meso-2,3-dimercaptosuccinic
acid (
DMSA) in children with markedly elevated blood lead (BPb) concentrations. Among 19 children with BPb concentrations of 50 to 69 micrograms/dl (2.41 to 3.33 mumol/L) who received a 5-day inpatient oral course of
DMSA (1050 mg/m2 per day), the mean BPb concentration decreased by 61%; in four who received
calcium disodium
ethylenediaminetetraacetic acid (CaNa2EDTA) (1000 mg/m2 per day intravenously), it decreased by 45% (p less than 0.0007). Urinary lead excretion was comparable in both groups. Treatment with
DMSA was more effective than treatment with CaNa2EDTA in restoring metabolic activity to the
heme pathway and was well tolerated even among nine patients who received concomitant
iron supplementation and two who had homozygous
deficiency of glucose-6-phosphate dehydrogenase. On discharge, these 19 children received either no
chelation therapy or
DMSA, 350 or 700 mg/m2 per day for 14 days on an outpatient basis. After 14 days the mean BPb values for the no-chelation, low-
DMSA, and high-
DMSA groups were 73%, 66%, and 50% of the pretreatment values, respectively. We conclude that a 5-day oral course of
DMSA is effective in the treatment of children with severe
lead poisoning. In addition, on an outpatient basis the administration of
DMSA, 700 mg/m2 per day, is capable of delaying the typical rebound in BPb values and should ultimately reduce the need for repeated hospitalizations.